Colon Cancer, Esophagus Cancer, Gastric Cancer, Hypoxia, Polyp of Colon
Conditions
Keywords
Hypoxia, Gastrointestinal endoscopes, High-flow nasal cannula Oxygenation
Brief summary
Hypoxia is the most common adverse event during gastrointestinal endoscopes sedated with propofol and sufentanil, especially in obese people. In the present study, high-flow nasal cannula oxygenation will be utilized in order to reduce the incidence of hypoxia among obesity.
Interventions
Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
DEVICERegular nasal cannula
Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
Sponsors
Shanghai Tongji Hospital, Tongji University School of Medicine
Shanghai Oriental Hospital, Tongji University School of Medicine
RenJi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* patients undergoing gastrointestinal endoscopes * age≥18 years old and ≤70 years old * patients or family members signed informed consent form * ASA classification I-II * BMI≥ 28kg/m²
Exclusion criteria
* Coagulation disorders or a tendency of nose bleeding; * An episode/exacerbation of congestive heart failure (CHF) that requires a change in medication, diet or hospitalization from any cause in the last 6 months; * Severe aortic stenosis or mitral stenosis; * Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months; * Acute myocardial infarction in the last 6 months; * Acute arrhythmia (including any tachycardia - or bradycardia) with the fluid of hemodynamics instability; * Diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy); * Increased intracranial pressure; * ASA classification Ⅲ-Ⅳ ; * Mouth, nose, or throat infection; * Liver and kidney disease * Fever, defined as core body temperature \> 37.5℃; * Pregnancy, breastfeeding or positive pregnancy test; * Emergency procedure; * Patients or family members refused to participate * Mental disorders and people without civil capacity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of hypoxia | Patients will be followed for the duration of hospital stay, an expected average of 2 hours] | (75% ≤ SpO2 \< 90% for \<60 s) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of subclinical respiratory depression | Patients will be followed for the duration of hospital stay, an expected average of 2 hours | (90% ≤ SpO2 \< 95%) |
| The incidence of severe hypoxia | Patients will be followed for the duration of hospital stay, an expected average of 2 hours | (SpO2 \< 75% for any duration or 75% \< SpO2 \< 90% for \>/=60 s) |
| Other adverse events include other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events. | Patients will be followed for the duration of hospital stay, an expected average of 2 hours | — |
Countries
China
Contacts
Primary ContactDiansan Su, Dr.
Outcome results
None listed